Alcresta Therapeutics Announces Appointment of Jason Weiner as Chief Commercial Officer
Alcresta Therapeutics Inc., a leading commercial-stage company focused on developing and commercializing novel, enzyme-based products, announced the appointment of Jason Weiner as its Chief Commercial Officer (CCO) effective July 27, 2020.
NEWTON, Mass., July 27, 2020 /PRNewswire-PRWeb/ -- Alcresta Therapeutics Inc., a leading commercial-stage company focused on developing and commercializing novel, enzyme-based products, announced the appointment of Jason Weiner as its Chief Commercial Officer (CCO) effective July 27, 2020.
"Recently Alcresta has experienced a period of rapid growth which requires a dynamic commercial leader to capitalize on near term opportunities while preparing launch strategies for our mid-range pipeline. Jason has demonstrated commercial success in rare disease, built and led high performance cross-functional teams, and most importantly, navigated the payer landscape to provide patients access to life changing therapeutics," said Daniel Orlando, CEO of Alcresta Therapeutics, Inc.
Mr. Weiner joins Alcresta with more than 17 years of industry and strategy consulting experience in the biopharmaceutical industry. Prior to joining Alcresta, Jason was the Vice President of Marketing and Market Access at Vericel Corporation, an autologous cell therapy company, where during his tenure he led all marketing and market access related activities for the cell therapy and regenerative medicine franchise. Included was the expansion and build-out of the commercial team and development of an innovative patient access and distribution program. Previously, Mr. Weiner was a consultant at Charles River Associates, where he advised on issues related to strategic customer engagements, payer marketing, drug launches, physician research, sales force alignment, market access, and pricing strategy.
Mr. Weiner shared, "I am excited to join Alcresta during this early stage of commercial growth and look forward to working to ensure providers and patients who can benefit from RELiZORB® have access to such an innovative product." Alcresta's first-in-class enzyme-based RELiZORB provides significant nutritional benefits for Orphan and Ultra-Orphan patient populations such as those with Cystic Fibrosis and Pancreatitis.
About Alcresta Therapeutics, Inc.
Alcresta Therapeutics, Inc. is dedicated to developing and commercializing novel, enzyme-based products designed to address challenges faced by patients living with gastrointestinal disorders and rare diseases. Alcresta currently markets RELiZORB for enterally fed patients with pancreatic insufficiency, which occurs in cystic fibrosis, pancreatic cancer and pancreatitis, and is developing platform applications for patients with short bowel syndrome (SBS) and prematurely born infants treated in the NICU. Alcresta Therapeutics, Inc. is backed by top-tier investors: Athyrium Capital Management, Bessemer Venture Partners, HealthQuest Capital, Frazier Healthcare Partners, and Third Rock Ventures. More information can be found at http://www.alcresta.com.
Internal Media Contact:
Daniel Orlando
Chief Executive Officer
Alcresta Therapeutics, Inc.
617-431-3600
SOURCE Alcresta Therapeutics, Inc.
Share this article